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Previous work has identified Mesp1 as an important regulator of the epithelialmesenchymal transition (EMT) and of cardiovascular cell fate in differentiating
embryonic stem cells (ESCs). To understand the molecular mechanisms underlying the
actions of Mesp1, we sought to identify transcription targets of Mesp1. Mesp1 rapidly
induced expression of PDGFR in differentiating ESCs and directly bound to
evolutionary conserved E-boxes within the PDGFR promoter. This result suggested
that PDGFR could be a direct target of Mesp1. However, we found that PDGFR was
not sufficient for the induction of EMT in ESCs or the induction of Flk1+ mesoderm, but
that it may play a role rather in the survival of Mesp1-induced mesodermal cells.
Although a clear role for Mesp1 in EMT and cardiovascular differentiation has
been established, its function in hematopoietic development is still unclear. Previous
lineage tracing demonstrated that Mesp1 activity labeled endothelial cells of embryonic
dorsal aorta, which recently was shown to give rise to definitive hematopoietic
progenitors. This suggested the potential that Mesp1 activity in endothelium might
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influence subsequent hematopoietic development. Although in vitro studies indicated
that Mesp1 acted to suppress emergence of hematopoietic progenitors, we made the
surprising observation in lineage tracing analysis of Mesp1 that all adult hematopoietic
progenitors and mature lineages were efficiently labeled by Mesp1-Cre, and further that
Mesp1 was necessary for hematopoietic differentiation of ESCs. In examining the
downstream targets of Mesp1 in ESC-derived endothelial cells, we identified myeloid
ecotropic viral integration site 1 (Meis1).
Meis1 forms a heterodimer with Pbx1 that augments Hox-dependent gene
expression. In addition, Meis1 has been associated with leukemogenesis and
hematopoietic stem cell self-renewal. In examining potential roles of Meis1 in
hematopoietic development, we identified two independent actions. One activity
regulated cellular proliferation of early hematopoietic progenitors. The second activity
was involved the fate choice between erythroid and megakaryocyte lineages. First, we
found that endogenous Mesp1 indirectly induces Meis1 and Meis2 in endothelial cells
derived from embryonic stem (ES) cells. Overexpression of Meis1 and Meis2 greatly
enhanced the formation of hematopoietic colonies from ES cells, with the exception of
erythroid colonies, by maintaining hematopoietic progenitor cells in a state of
proliferation. Second, overexpression of Meis1 repressed the development of early
erythroid progenitors, acting in vivo at the megakaryocyte-erythroid progenitor (MEP)
stage to skew development away from erythroid generation and toward megakaryocyte
development. This previously unrecognized action of Meis1 may explain the embryonic
lethality observed in Meis1-/- mice that arises from failure of lymphatic-venous separation,
and which can result as a consequence of defective platelet generation. These results
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show that Meis1 exerts two independent functions, with its role in proliferation of
hematopoietic progenitors acting earlier in development from its influence on the fate
choice at the MEP between megakaryocytic and erythroid development.
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CHAPTER 1: INTRODUCTION
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The embryonic stem cell model system
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of
blastocyst-stage embryos.1,2 These cells have two unique characteristics. First, they can
be maintained and expanded as pure populations of undifferentiated cells in culture.
Second, they are pluripotent and possess the capacity to generate every cell type in the
body. The pluripotent nature of mouse ES cells was formally demonstrated by their
ability to contribute to all tissues of adult mice, including the germ line, following their
injection into host blastocysts.3 In addition to their developmental potential in vivo, ES
cells display a remarkable capacity to form differentiated cell types in culture. Under
appropriated conditions, ES cells will differentiate and generate progeny consisting of
derivatives of three embryonic germ layers: mesoderm, endoderm, and ectoderm.4,5
Studies during the past 30 years have led to the development of appropriate culture
conditions and protocols for the generation of a broad spectrum of lineages.
The ability to derive multiple lineages from ES cells opens exciting new
opportunities to model embryonic development in vitro for studying the events regulating
the earliest stages of lineage induction and specification. Findings from several different
studies have demonstrated striking parallels between the ES cell model and the early
embryo. In addition, ES cell model enable us to access cells at different stages of
development and to use a combination of genetic, molecular biology and tissue culture
tools to study developmental processes when such studies are difficult in the mouse
embryo and impossible in the human embryo. Mesoderm-derived lineages, including the
hematopoietic, vascular, and cardiac, are among the easiest to generate from ES cells and
have been studied in considerable detail. In addition to providing a model of early
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development, the ES cell differentiation system is viewed as a novel and unlimited source
of cells and tissues for transplantation for the treatment of a broad spectrum of diseases.

The role of Mesp1 in embryogenesis and mouse ESC differentiation
Mesp1, a basic helix-loop-helix transcription factor, is one of the earliest markers
for the vertebrate cardiovascular development. 6 It is transiently expressed in the
primitive steak at the onset of gastrulation (E6.5) and in the prospective cardiac
mesoderm and is then rapidly downregluated after E7.5.7 Lineage tracing studies
suggest that Mesp1 is expressed by almost all precursors of the cardiovascular system.8
Mesp1-deficient mice show aberrant heart morphogenesis that resulted in cardia bifida.8
Recently, by taking advantage of the in vitro ESC differentiation model, our lab and other
two groups demonstrate that Mesp1 acts as a master regulator during cardiovascular
specification (Figure 1.1).9-11 Transient Mesp1 expression in ESCs is sufficient to
promote a restricted set of cardiovascular fates including cardiomyocytes, smooth muscle
cells and endothelial cells. Our group also suggested Mesp1 induces features of EMT
and snai1 in differentiating ESCs, consistent with a role in gastrulation.12 In addition,
Bondue et al. found Mesp1 induction leads to a transient inhibition of apoptosis of
differentiating ESCs.9
Although a clear role for Mesp1 in cardiovascular differentiation and EMT has
been established, its function in hematopoietic development is still unclear. Our in vitro
studies indicated that Mesp1 acted to suppress emergence of hematopoietic progenitors,
although we did not establish if this action occurred in vivo. Previous lineage tracing
demonstrated that Mesp1 activity labeled endothelial cells of embryonic dorsal aorta,
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which recently was shown to give rise to definitive hematopoietic progenitors. This
suggested the potential that Mesp1 activity in endothelium might influence subsequent
hematopoietic development.
It is important to identify transcriptional targets of Mesp1 to understand its actions.
The effect of Mesp1 on myocardial differentiation was ascribed to the ability of Mesp1 to
directly transactivate Dkk1 expression.11 However, our group showed Dkk1 alone was
not sufficient for the observed Mesp1 effects, and Bondue et al. further clarified that
Dkk1 was not a direct target of Mesp1 by chromatin immunoprecipitation (ChIP) in
differentiating ESCs.9,10 Instead, based on evidence from ChIP assays, Bondue et al.
suggested that Mesp1 directly activated the core cardiac transcription factors Hand2,
Nkx2.5, Myocd and Gata4.9 However, these genes were not upregulated until 24 or 48
hours after Mesp1 induction based on our microarray expression data. Instead, we found
a group of genes which were induced by Mesp1 within 6 or 12 hours.10 Since direct
Mesp1 targets should be induced earlier than indirect targets, these genes may represent
additional direct targets of Mesp1.

PDGFR and its developmental functions
PDGFR is one of those genes which were induced by Mesp1 within 6 hr.
PDGFRs and their ligands (PDGFs) have served as prototypes for receptor tyrosine
kinase and growth factor function for a long time. In higher vertebrates, there are two
PDGF receptors, PDGFR and PDGFR, which form both homo- and hetero-dimers.
The cellular processes that depend on PDGFR signaling include cell survival, cell
proliferation and directed cell migration, and signaling through PI3K-Akt downstream
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appears to be critical for these processes.13 Embryogenesis studies suggest an
evolutionary conserved role for PDGFR signaling during gastrulation of a variety of
organisms, including frog, zebrafish, and sea urchin.14-17 In Xenopus embryos, the
involuting mesodermal cells fail to migrate beneath the blastocoel roof ectoderm but
undergo apoptosis upon PDGFR inhibition. Rescue from apoptosis did not rescue the
migration defect, suggesting that PDGFR signaling independently controls both
processes.18 Recently, PDGFR signaling is shown to control the migration of
mesoderm cells during chick gastrulation.19 Both expression of a dominant-negative
PDGFR and depletion of endogenous PDGFR ligands inhibit the migration of
mesoderm cells after their ingression through the primitive streak.
Since the double Mesp1/2 null mice exhibit a similar defect in gastrulation which
is the mesodermal cells fail to migrate out from the primitive streak,12 it is possible that
PDGFR acts downstream of Mesp1 in mouse gastrulation. Although PDGFA is
expressed in the epiblast and PDGFR is expressed in the nascent mesoderm during
mouse gastrulation, a role for PDGFR signaling in mouse gastrulation is not
apparent.20,21 PDGFA and PDGFR-null mouse embryos nevertheless show severe
impairment of early mesenchymal derivatives in both embryo and extraembryonic tissues
and die during gestation.22 However, the gastrulation defects in PDGFR-null mice
might be compensated by PDGFR or other factors. A recent paper shows that Mesp1cre-mediated conditional knockout mice of both PDGFR and PDGFR don’t result in
an observable cardiac phenotype.23 However, as we have shown PDGFR is an early
target of Mesp1 and therefore some PDGFR might have been transcribed before the
Mesp1-cre-mediated deletion occurs, the early gastrulation defects can be masked. Due
5

to the complexity and technique difficulties of in vivo study, ES cell differentiation model
might be a good alternative for us to understand PDGFR and its transcriptional and
functional relationships with Mesp1.

Hemogenic endothelium
During embryonic development, hematopoietic stem cells (HSCs), which give rise
to adult blood system, and endothelial cells, which line blood vessels, both form from the
mesodermal germ cell layer; but exactly how is debatable. Two theories have been
proposed. One is that both hematopoietic and endothelial cells arise from a mesodermderived common precursor called a hemangioblast. The other theory proposes that HSCs
derive from a subset of early endothelial cells known as hemogenic endothelium. Using
time-lapse imaging with live markers and genetic analysis of differentiating ESCs, two
groups revealed that hematopoietic cells were generated from hemogenic endothelium in
vitro.24,25 Moreover, recent studies using in vivo imaging directly observed that HSCs
emerging from aortic endothelium during both zebrafish and mouse development.26-28
These studies clearly demonstrated the presence of hemogenic endothelium in mouse
embryo and it is the origin of HSCs. However, the molecular mechanism underlying the
transition from hemogenic endothelium to nascent HSCs remains unclear.

Meis1 protein and its regulation
Meis1 was identified as a common site of proviral integration by the ecotropic
virus in BXH-2 mice that promoted myeloid leukemias.29,30 Meis1 belongs to the TALE
class of homeodomain transcription factors characterized by a three amino acid loop
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extension between the -helices within its homeodomain (Figure 1.2A). Meis1 interacts
with other homeodomain proteins,31 in particular Pbx1,32 forming a heterodimer that
recognizes DNA (Figure 1.2B). The Meis1 protein contains a domain that recognizes
wild-type Pbx proteins, but not chimeric Pbx1 proteins formed by translocations such as
the E2a-Pbx1 oncoprotein.33 The Meis1/Pbx dimer cooperatively associates with Hox
homeodomain proteins, and in vitro interaction between Meis1, Hoxa9 and Pbx proteins
can occur in the absence of DNA.34 In addition to its Pbx interaction motif (PIM), 33
Meis1 also contains a carboxyl-terminal (C-terminal) region that is required for leukemia
induction.35 This C-terminal region of Meis1 contains transcriptional activity regulated
by protein kinase A (PKA) that appears dependent upon the co-activator of cAMP
response element-binding protein (CREB), CREB-binding protein (CBP).36 Thus, Meis1
appears to augment Hox transcription factor activity and can be regulated by extracellular
signaling cues.

The role of meis1 in leukemogenesis
Initial analysis of Meis1 focused on its role in leukemic transformation. Acute
myeloid leukemia (AML) induced by Hoxa9 was significantly accelerated by coexpression with Meis1, but not by co-expression with Pbx1b.37 A cellular action of
Meis1 appeared to be the suppression of differentiation and the promotion of proliferation
in a system of cytokine driven Hoxa9-immortalized cells.38 A Hoxa9 chimeric fusion
protein, NUP98-Hoxa9, independently induced a silent pre-leukemic phase of disease
which was accelerated by Meis1, suggesting that Meis1 augments the activities of the
Hoxa9-dependent transformational event.39 Interactions between Meis1 and Hoxa9 also
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occur in a model of leukemia induced by rearrangements of the MLL/ALL1 gene, which
represents approximately 20% of acute lymphoblastic leukemias and 5-6% of AML.40 In
this setting, Meis1 is an essential, rate limiting regulator of the development of MLLdependent leukemias.40,41

The role of Meis1 in hematopoiesis
Studies based on Meis1 overexpression initially suggested a role in regulation of
proximodistal limb axis development. 42 However, studies based on targeted disruption of
Meis1 in mice observed more substantial defects in hematopoiesis, angiogenesis and eye
development.43-45 Complete elimination of Meis1 by gene targeting caused death
between embryonic day 11.5 and 14.5.44 While definitive myeloerythroid lineages are
present in Meis1-/- embryos, the total numbers of colony-forming cells are significantly
reduced. Similar defects were observed when Meis1 was targeted by a strategy that
potentially generated a dominant negative protein, but in this case defects were also
observed in the developing eye, with partially duplicated retinas and smaller lenses. 43
This latter effect potentially could represent interference with the normal actions of Meis2,
rather than Meis1, since Meis2 has been demonstrated to regulate the expression of Pax6,
a pivotal regulator of eye development. 46 Meis2 has been shown to maintain retinal
progenitor cells in a state of rapid proliferation, at least in part through regulation of cell
cycle machinery including cyclin D1.47
Early embryonic lethality due to Meis1 deficiency was initially thought to result
from hemorrhage secondary to vascular defects, 43,44 but subsequent studies demonstrated
that the absence of platelets in Meis1-/- embryos leads to a failure in separation of
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lymphatic vessels during embryonic angiogenesis, 45 as platelets are critical in mediating
separation of the venous and lymphatic systems. 48,49 Further studies have recognized
additional defects in heart development in Meis1-/- embryos.50
While Meis1 promotes leukemogenesis and normal hematopoiesis by modulating
self-renewal of progenitor-like cells, the basis for this action as well as the defect in
platelet development in Meis1-/- mice are still incompletely understood.

The transcriptional targets of Meis1
The oncogenicity of Meis1 has been linked to its transcriptional activation of
downstream effectors Flt3, Cd34, Erg, c-Myb, Trib2 and Ccl3.51-53 CyclinD has also
been shown as a direct target of Meis1 in leukemogenesis.54 However, only a few of
transcriptional targets of Meis1 involved in normal hematopoiesis have been identified.
Studies in zebrafish showed that Meis1 and Pbx act upstream of gata1 to regulate
primitive hematopoiesis.55,56 Megakaryocytic gene PF4 and HSC-specific gene Hif-1
have been shown to be direct targets of Meis1 in normal hematopoiesis.57,58 Although a
very recent study has mapped the genome-wide DNA binding sites of Meis1 in
hematopoietic progenitor cells using ChIP-seq,59 none of these targets has been
functionally validated. Therefore, identifying transcriptional targets of Meis1might be
important for the understanding of its actions during both leukemogenesis and normal
hematopoiesis.
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Figure 1.1 The role of Mesp1 in ES cell differentiation.
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Figure 1.2 The protein structure and binding properties of Meis1 protein.
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CHAPTER 2: EXPERIMENTAL PROCEDURES

12

Mouse ES cell generation and embryoid body (EB) differentiation
To generate inducible ES cell lines (A2lox.Mesp1, A2lox.Mesp2,
A2lox.PDGFR, A2lox.Meis1, A2lox.Meis2, A2lox.Plac8, A2lox.Serpinb2,
A2lox.Meis1a, A2lox.Meis2(2a), A2lox.Meis2(4a), and A2lox.HoxA9), individual
cDNAs were amplified from EB RNA using gene-specific primers (Table 2.1) and cloned
into the p2lox targeting vector.60 Site specific recombination into A2lox ESCs was
performed using co-transfected Cre recombinase (Figure 2.1), and all A2lox ESC lines
were maintained as described.10
To generate inducible ES cell lines (A2lox.Plac8tetSerpinb2,
A2lox.Meis1tetHoxA9, A2lox.HoxA9tetMeis2, A2lox.bio-Mesp1tetBirA), an inducible,
dual-expression vector was prepared by cloning a cDNA (Serpinb2, HoxA9, BirA or
Meis2) into the vector pTet-CMVminpA-zeocin (Dr. Jonathan Green, Washington
University School of Medicine), transferring this Tet-CMVmin promoter-cDNA-pA
cassette into the p2lox targeting vector downstream of the original p2lox pA site, and
followed by inserting a second cDNA (Plac8, Meis1, Mesp1 or HoxA9) into the resulting
plasmid, allowing simultaneous dox induction of both cDNAs in transfected A2lox ESCs.
For differentiation, ESCs were plated in suspension in Petri dishes at 1.5×10 4
cells/ml in Iscove’s modified Dulbecco’s medium (IMDM) with 10% FCS, nonessential
amino acids, L-glutamine, Na Pyruvate, Pen/Strep, and 2-mercaptoethanol as described,10
and supplemented where indicated with Dkk1 or SC-51322 (Enzo Life Sciences). Gene
expression was induced by addition of doxycycline (250-500 ng/ml).
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Generation of recombinant Dkk1-his
A PCR product generated using the primers 5′Hind III Dkk1
(CCAAAGCTTCGGAGATGATGGTTGTGTG) and 3′Age I Dkk1
(GCAACCGGTGTGTCTCTGGCAGGTGTGGA) and cDNA from day 4 embryoid
bodies was digested with Hind III and Age I and ligated into Hind III- and Age I-digested
pcDNA4-myc-hisA to generate a C-terminal 6His tag in frame with full length Dkk1.
The resulting plasmid, pcDNA-Dkk1-his, was transfected into 293F/T cells (Invitrogen)
using Ca2PO4 precipitation. Supernatants from transfected cells were adjusted to pH 8.0
by the addition of 1/3 volume of 1× Ni-NTA binding buffer and then purified on Ni-NTA
His•Bind resin (Novagen). Purified Dkk1-his was dialyzed against two changes of PBS,
and was shown to consist predominantly of a closely spaced doublet (Mr=35×103) that
was recognized by an antibody to penta-His (Qiagen) on Western analysis. Activity of
purified Dkk1-his was confirmed by ability to inhibit SUPER8×TOPFlash reporter
activity. Dkk1-his and commercially available Dkk1 were further demonstrated to
display no substantial cytotoxic effects.

Gene expression analysis
RNA from FACS-sorted cell populations was extracted using RNeasy kits
(Qiagen, Germantown, MD), and cDNA was synthesized using Superscripts III
(Invitrogen, Carlsbad, CA). Quantitative RT-PCR was performed using SYBR Green
PCR Master Mix (Applied Biosystems, Carlsbad, CA) and a StepOne Plus Real Time
PCR System (Applied Biosystems) with Intron-spanning, gene-specific primers shown in
Table 2.1. Large-scale gene expression analysis of A2lox.Mesp1 samples was done
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using Affymetrix MOE430_2.0 arrays as described. 10 Data were normalized and
modeled using DNA-Chip Analyzer/dChip. For A2lox.Meis1 and A2lox.Meis2 samples,
gene expression analysis was done using Affymetrix Mouse Gene 1.0 ST arrays, and data
was normalized and modeled using ArrayStar. The microarray datasets were deposited in
the NCBI GEO database under accession numbers GSE34537 (A2lox.Mesp1 data),
GSE34543 (A2lox.Meis1 data), and GSE34541 (A2lox.Meis2 data).

Luciferase assay
293T cells were transfected with firefly luciferase reporter constructs containing a
minimal CMV promoter (CMVmini), or enhancers/promoters for Epha4, Nkx2.5, Myocd,
Meis1 or Meis2 cloned upstream of CMVmini using primers indicated in Table 2.1, along
with expression vectors for Mesp1 and E47, either separately or together. Cells were
harvested 24 hr later and lysed. Luciferase activity was determined from 20 l of cell
extract in triplicate, using the luciferase assay substrate with an Opticomp II automated
luminometer (MGM Instruments, Hamden, Conn.), reading relative light activity for 20
sec. Firefly luciferase activity was normalized using co-transfected Renilla luciferase
construct (prL-CMV) to account for possible differences in cell density and transfection
efficiency.

EMSA
A2lox.bio-Mesp1tetBirA ESCs were differentiated in the presence of Dkk1, with
or without Dox (250 ng/ml) treatment on day 2. After 36 hr, cells were harvested and
nuclear extract was prepared. Complementary double-stranded oligonucleotides (Table
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2.2) containing the evolutionary conserved E-boxes within PDGFR  promoters were
radiolabeled with [-32P] dCTP as previously described.61 Radiolabeled probe (5.0 ×104
cpm) was incubated for 30 min on ice or at room temperature in binding reaction buffer61
with 5 g of whole cell extract and 1 g of poly (dI-dC). For antibody supershifts in
EMSAs, whole cell extract was incubated with anti-biotin antibody on ice for 15 min
before adding radiolabeled probes as indicated. The final reaction mixture was
electrophoresed through a nondenaturing 5% polyacrylamide gel at 150 V for 2 h at room
temperature in 0.4× TBE buffer (l× TBE is 89 mM Tris [pH 8.2], 89 mM boric acid, and
2 mM EDTA).

MicroRNA-mediated knockdown
Four miR30-based shRNA (Ptger3mir1-4) cassettes, described in Table 2.3,
directed against the target gene Ptger3 were cloned into vector pcDNA3.1 zeo/(+) Vav1
mir-shRNA (from Dr. Andrew Shaw, Washington University School of Medicine, St.
Louis, MO) using Xho I and EcoR I, and then subcloned into p2lox.CAGGFP.MCS.pA, a
vector expressing GFP, at the Nhe I and EcoR V sites in the 3' UTR downstream of the
GFP coding exon. A2lox ES cell lines with constitutive expression of shRNA targeting
Ptger3 were generated. The extent of knockdown of the Ptger3 was assessed by
quantitative RT-PCR.

ES/OP9 co-culture
Day-6 EBs were trypsinized to single cell suspensions and plated on a monolayer
of irradiated OP9-GFP cells62 at a density of 100,000 cells/ml in IMDM with 10% FCS,
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nonessential amino acids, L-glutamine, Na Pyruvate, Pen/Strep, 2-mercaptoethanol and
cytokines (100 ng/ml recombinant murine (rm) stem cell factor (SCF), 40 ng/ml rm
thrombopoietin (TPO), 40 ng/ml rm vascular endothelial growth factor (VEGF), 5% Flt3
ligand conditioned medium (Flt3L), 10 ng/ml rm interleukin-3 (IL-3), and 20 ng/ml rm
IL-6). All cytokines are from PeproTech.

FACS analysis and sorting
EBs or ES/OP9 co-cultures dissociated by trypsin, or blood cells collected from
mouse bone marrow (BM), spleen or peripheral blood were treated with Fc block (BD
Biosciences Pharmingen) on ice for 5 min and then stained with antibodies. Primary
antibodies: PE -Tie2 (1 g/ml, TEK4), peridininchlorophyll protein (PerCp)-Cy5.5 CD16/32 (1 g/ml, 93), PE -Flk1 (1 g/ml, Avas12a1), PE-Cy7 -CD41 (1 g/ml,
eBioMWReg30), allophycocyanin (APC) -PDGFR (1 g/ml, APA5), APC -Flk1 (1
g/ml, Avas12a1), APC -CD150 (1 g/ml, mShad150), APC -AA4.1 (1 g/ml,
AA4.1), APC -CD42d (1 g/ml, 1C2), APC-eFluor 780 -c-kit (1 g/ml, 2B8), APCeFluor 780 -CD45.2 (1 g/ml, 104), eFluor 450 -B220 (1 g/ml, RA3-6B2), and
eFluor 450 -CD105 (1 g/ml, MJ7/18) (eBioscience), PE -CD71 (1 g/ml, C2), PECy7 -Sca1 (1 g/ml, D7), PE-Cy7 -Mac1 (1 g/ml, M1/70), APC -Gr1 (1 g/ml,
RB6-8C5), SA/PE-Cy7 (BD Biosciences Pharmingen), V500 -B220 (1 g/ml, RA36B2, BD Hrizon), biotin -mE-cadherin (1.25g/ml, R&D Systems), PE or APC hCD4 (1 g/ml, Invitrogen). Data were acquired on a FACS Canto II (BD Biosciences)
and analyzed using FlowJo 7.6.5 (Tree Star). A2lox.Mesp1 cells were sorted based on
Flk1 and Tie2 expression by using a MoFlo cytometer (Dako North America).
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A2lox.Meis1 or A2lox.Meis2 cells were sorted on the FACS Aria II (BD Biosciences)
based on levels of CD41 expression.

Colony-forming assay
Day-6 EBs were dissociated by trypsin and added to MethoCult GF M3434
methylcellulose-based medium (StemCell Technologies, Vancouver, BC) for
hematopoietic colonies. Methylcellulose suspension cultures were supplemented with
doxycycline where indicated. All colonies were counted on day 6 of methylcellulose
culture. Megakaryocyte progenitors were examined using MegaCult-C collagen-based
medium supplemented with 50 ng/mL rm TPO, 10 ng/mL rm IL-3, 20 ng/mL rm IL-6,
and 50 ng/mL rm IL-11, following the protocol provided by the vendor (StemCell
Technologies, Vancouver, BC). Megakaryocytic colony formation was assessed after
growth for 6 days by dehydrating, fixating, and staining the slides with acetylthiocholine
iodide (Sigma-Aldrich) and Harris hematoxylin (Sigma-Aldrich) counterstain. The
acetylthiocholine iodide-stained colonies were counted. Bright field images were
captured by a Nikon Eclipse TS100 microscope with an Optronics 60800 camera, and
imported into MagnaFire 2.0 software.

Retrovirus production and cell infection
Meis1a, Meis1b and Meis2(2b) were subcloned from p2lox constructs into IREShuman CD4 (hCD4)-retrovirus (RV)63 with EcoR I. BM cells were collected from 8- to
10-week-old 129S6/SvEvTac mice (Taconic, Germantown, NY) and c-kit+ progenitor
cells were enriched with CD117 MicroBeads as described by the vendor (Miltenyi
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Biotec). c-kit+ BM progenitors were expanded in IMDM medium with 10% FCS, 100
ng/mL rm SCF and 50 ng/mL rm TPO overnight, and then infected with retroviral
supernatant in the presence of polybrene (2 g/ml) by spin infection.

BrdU labeling
Bromodeoxyuridine (BrdU) was added to ES/OP9 co-cultures 3 hours before
harvesting the cells for FACS analysis. The percentage of BrdU-positive cells among
CD41+ cells was assessed by cell-surface marker staining followed by cell
permeabilization and APC α-BrdU antibody staining (BD Biosciences Pharmingen).

Apoptosis assay
To analyze the degree of apoptosis of CD41+ cells, ES/OP9 co-cultures were
disaggregated and stained with CD41 antibody on ice for 30 minutes. After one wash in
1×Binding Buffer (BD Biosciences), per 1× 105 cells were stained with 5 l PE-Annexin
V (BD Biosciences Pharmingen) and 5 l cell viability dye 7-amino-actinomycin D (7AAD) for 15 minutes at room temperature. The proportion of cells in different quadrants
was determined by FACS.

BM transplantation
24 hours after infection, c-kit-enriched BM progenitor cells were washed in
1×PBS and transplanted by retro-orbital injection into 129S6/SvEvTac recipients that had
been sub-lethally irradiated at 600 cGy.
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BM chimeras
BM cells were collected from 8- to 10-week-old Plac8-/- or wild type C57BL/6J
background littermate control mice (Jackson Laboratory; CD45.2+) and transplanted by
retro-orbital injection with competitor marrow (B6.SJL-Ptprca/BoyAiTac; Taconic;
CD45.1+) at 1:1 ratio into B6.SJL-Ptprca/BoyAiTac recipients that had received 1,100
cGy. Donor-derived cells in BM (CD45.2+) were analyzed 4 weeks after transfer by
FACS analysis.

Mice
Mesp1-Cre mice were obtained from the Riken BioResource Center as cryopreserved embryos.6 Heterozygous Mesp1Cre/+ mice were bred to homozygous Rosa26CAG-STOP-eGFP+/+ reporter mice. To generate Rosa26-CAG-STOP-eGFP+/+ reporter
mice, the plasmid pCAG-Cre:GFP (Addgene plasmid 13776)64 was digested with EcoR I
and Sal I and the CAG-promoter containing 1718 bp fragment was cloned bluntly into the
Pac I site of a modified version of pROSA26-1 (Addgene plasmid 11739).65 The
resulting plasmid was digested using Pvu I and the gel purified 13366 bp fragment was
electroporated into the 129SvEv ES cell line, EDJ 22 (ATCC number: SCRC-1021).
Targeted clones were identified by Southern blot analysis using probes cloned from
isogeneic genomic ES cell DNA using oligonucleotides 5'CTCACTCAGCCCGCTGCCCGAG and 5'-CTCCCGCCAGAGTCCCGATCCCC
(probe A), and 5'-GGCTTGTTGGTTCCATACATCTACTGG and 5'GATCAAGATGAAGGAAGAGACCCTCC (probe B). Mice were generated by
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injecting targeted ES cells into C57BL/6J blastocysts and maintained on a 129
background after transmission of the targeted allele through the male germ line.

Statistical analysis
Error bars in all panels represent standard deviation (SD). Paired student’s t-tests
were performed to calculate P values and are indicated in the graph.
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Table 2.1 Oligonucleotide primers used in this study

Name
Meis1a_F
Meis1a_R
Meis1b_F
Meis1b_R
Meis2(2a)_F†
Meis2(2a)_R†
Meis2(2b)_F†
Meis2(2b)_R†
Meis2(4a)_F†
Meis2(4a)_R†
Mesp1_F
Mesp1_R
Mesp2_F
Mesp2_R
PDGFR_F
PDGFR_R
Plac8_F1
Plac8_R1
Serpinb2_F
Serpinb2_R
HoxA9_F
HoxA9_R
Meis1_P_F
Meis1_P_R
Meis2_P_F
Meis2_P_R
Epha4_Enh_F
Epha4_Enh_R
Nkx2.5_Enh_F
Nkx2.5_Enh_R
Myocd_Enh_F
Myocd_Enh_R

Name
Plac8_F2
Plac8_R2
Ptger3_F
Ptger3_R
Gapdh_F

Cloning Primers
Sequence
GAAGTAGGAAGGGAGCCAGAGAGG
CACCATTGTAGACAACGCATATTCCC
GAAGTAGGAAGGGAGCCAGAGAGG
CACCATTGTAGACAACGCATATTCCC
TACGACACATCCAGGAGTTTATTG
GTGTGTTTCCTTCTTCCTTGAGTT
TACGACACATCCAGGAGTTTATTG
GTGTGTTTCCTTCTTCCTTGAGTT
TACGACACATCCAGGAGTTTATTG
GTGTGTTTCCTTCTTCCTTGAGTT
AATGGTCAGGCCTCCGTTGC
TGTCCCCTCCACTCTTCAGGCA
GGTCCAGCTTCCCAGAGTCA
GGTGCAGGTAAGGCCATATTA
GGAAGGACTGGAAGCTTGG
GCTCTAGAAGGTTATCCCGAGGAGGC
TTTTGAGACCTCGCATCGAA
TCTTGCCATCCAGCTCCTTA
AGCTGTGTAGAGGATTGAAACAATG
GCTACAAAACCTCATGTGGAAATAG
GCGCCGGCAACTTATTAG
ACAGAGGGAGACGGACAGTC
CGGGATCCTTTTTCTCTGGAACTGGGAGC
GAAGATCTGCGTGTGTAAAGTGTGTGTTG
CGGGATCCTGTACCGTACTTTCCCTGTGG
GAAGATCTCCAAACCAAGGAGACTTCTC
CTGACGTTGCCCTTGACTAAG
AGGCATAGGCAGTACACTTTC
AAGCACGGGCCAGGCCAA
TGCCTTTTAAAGACTTGGTGC
TCCTGTGTTTTCTGACTGGGT
GGCTACTTGACTTTTCTGCAG
Quantitative RT-PCR Primers
Sequence
ATTTGTAGTAAGACTCAACCCCAGAC
CAGACAACACTCATTCATGTCAG
GGGATCATGTGTGTGCTGTC
AGCAGATAAACCCAGGGATC
TGCCCCCATGTTTGTGATG
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Gapdh_R
Mesp1_F
Mesp1_R
Mesp2_F
Mesp2_R
Meis1a_F
Meis1a_R
Meis1b_F
Meis1b_R
Meis2(2a)_F
Meis2(2a)_R
Meis2(2b)_F
Meis2(2b)_R
Meis1_F
Meis1_R
Meis2_F
Meis2_R

TGTGGTCATGAGCCCTTCC
AGAATCGTGGGACCCATCGTTC
ATTGTCCCCTCCACTCTTCAGGC
CCACTGAACCTGCAGAGCTGACTAAAG
AGATAAAGGCACTTCCAAGGC
TCCAGCATCTAACACACCCTTAC
CATTCCACTCATAGGTCCTGG
TCCAGCATCTAACACACCCTTAC
GGCATACTTTGCAGCCCTGG
AAATCGAGCAGTGAGCCAAG
CGAAGGTTACATATAGTGCCACTG
AAATCGAGCAGTGAGCCAAG
GGCATGCTCTGCAAACCTGCA
TCCAGCATCTAACACACCCTTAC
AAAACCTCCCATTGGCTGTC
ACAACAGCAGTGAGCAAGGC
GGGTACGGGTGTGTGAGATG



Meis1a and Meis1b were cloned using the same primers and distinguished by
sequencing.
†

Meis2(2a), Meis2(2b), and Meis2(4a) were cloned using the same primers and
distinguished by sequencing.
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Table 2.2 EMSA probes
Name
Epha4 E3_F
Epha4 E3_R
PDGFR E1_F
PDGFR E1_R
PDGFR E2_F
PDGFR E2_R
PDGFR E3_F
PDGFR E3_R
PDGFR E4_F
PDGFR E4_R
PDGFR E5_F
PDGFR E5_R
PDGFR E6_F
PDGFR E6_R
PDGFR E7_F
PDGFR E7_R
PDGFR E8_F
PDGFR E8_R
PDGFR E9_F
PDGFR E9_R
PDGFR E10_F
PDGFR E10_R
PDGFR E11_F
PDGFR E11_R
PDGFR E12_F
PDGFR E12_R
PDGFR E13_F
PDGFR E13_R
PDGFR E14_F
PDGFR E14_R

Sequence
GAGGTGGGCACATTTGTCCAAAA
GCCATTTTGGACAAATGTGCCCA
GCTATTTACTTTAAGCAAATGATTAGTTTT
TCGAAAAACTAATCATTTGCTTAAAGTAAA
TCGACCCCACCCCATCTGGTTTGCT
GGGGAGCAAACCAGATGGGGTGGGG
CCTGAAGGAACATGTGGAAGTAATAGT
GCTCACTATTCATTCCACATGTTCCTT
TGTGAAGTTACCATTTGTGGGAGGA
GTTCTCCTCCCACAAATGGTAACTT
TACCAGAAGAGCAACTGGGTGCT
GTATCGAGCACCCAGTTGCTCTT
GGAAACCTTTAGCAAATGTTTGTTAAT
GATCATTAACAAACATTTGCTAAAGGT
TGTCACACATGGAAACCTTTAGCAAATGTT
TCGAAACATTTGCTAAAGGTTTCCATGTGT
CTTTGCCCAACCATTTGCTTGCCTG
GGAGCAGGCAAGCAAATGGTTGGG
TGCAGGCAAGGCAGATGCTTTG
ACCCAGCAAAGCATCTGCCTTG
AGGGACTCCAACATCTGGTTGCCG
GATGCGGCAACCAGATGTTGGAGT
CTCCGAAGCCACAGCTGTGAGCTGGG
GCTTCCCAGCTCACAGCTGTGGCTT
AATGACAAACACATTTGGCCT
CACTCGAGGCCAAATGTGTTTGT
CGCATTCCAGCAACTGGGATTTGAGG
GAAATTCCTCAAATCCCAGTTGCTGGAA
TCTCAGGTCGCAGTTGAAAACAA
TGCATTGTTTTCAACTGCGAC
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Table 2.3 MicroRNA knockdown sequences

Name
Ptger3mir1

Ptger3mir2

Ptger3mir3

Ptger3mir4

mir30-based shRNA cassettes
Sequence
TGCTGTTGACAGTGAGCGAGGAGAAGTTTAGCTAAAGACATA
GTGAAGCCACAGATGTATGTCTTTAGCTAAACTTCTCCCTGCC
TACTGCCTCGGA
TGCTGTTGACAGTGAGCGAGGTTGAGCAATGCAAGACACATA
GTGAAGCCACAGATGTATGTGTCTTGCATTGCTCAACCGTGC
CTACTGCCTCGGA
TGCTGTTGACAGTGAGCGATGCCAAGAAGGTATACAGTACTA
GTGAAGCCACAGATGTAGTACTGTATACCTTCTTGGCACTGC
CTACTGCCTCGGA
TGCTGTTGACAGTGAGCGAAGGGAAGGATGACTGAGTATTTA
GTGAAGCCACAGATGTAAATACTCAGTCATCCTTCCCTGTGC
CTACTGCCTCGGA
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Figure 2.1 Schematic of p2lox targeting strategy. Plasmid and cells are from Michael Kyba; figure adapted from M. Kyba and R.C.
Lindsley.
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CHAPTER 3: IDENTIFICATION OF TRANSCRIPTONAL TARGETS OF
MESP1
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Mesp2 has similar actions to Mesp1 on induction of mesoderm markers and induction
of EMT
Since Mesp2 can compensate for migratory defects in Mesp1-deficient embryos,12
we asked if Mesp2 can induce mesoderm and EMT in differentiating ESCs (Figure 3.1).
Dox treatment of A2lox.Mesp2 cells induced expression of Flk1 and PDGFR (Figure
3.1A), downregulated E-cadherin (Figure 3.1A), and induced Snai1 expression in Dkk1
treated cultures (Figure 3.1B). Thus, the ability of differentiating Mesp1-deficient ESCs
to express Snai1 and undergo EMT may be due to compensation by Mesp2.

Identification of early transcriptional targets of Mesp1 activity
We used reporter analysis to ask if Nkx2.5 or Myocd were direct targets
of Mesp1 (Figure 3.2A). Activation of the Epha4 enhancer required both Mesp1 and E47,
as expected.66 However, cardiac-specific enhancers for Nkx2.567 and Myocd68 were not
activated by cotransfection of Mesp1 alone or with E47, indicating they may not be direct
targets of Mesp1. However, other enhancer regions of Nkx2.569 or Myocd might be
responsive to Mesp1, or other factors not present in 293T cells may be required in order
for Mesp1 to act.

PDGFR is induced rapidly by Mesp1 in a dose-dependent manner
Since direct Mesp1 targets should be induced earlier than indirect targets, we
characterized Mesp1-induced gene expression after 6, 12, and 24 hr of dox treatment on
day 2 of differentiation in DKK1-treated cultures (Figure 3.2B-C). After 6 hr, 41 genes
were induced >3-fold; after 12 hr, 152 genes were induced; and after 24 hr, >500 genes
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were induced. Among these genes, the expression of PDGFR increased progressively
from 14-fold induction at 6 hr to more than 200-fold induction at 24 hr following Mesp1
induction (Figure 3.3A). The protein level of PDGFR is also upregulated at the early
time points of Dox treatment in a dose-dependent manner (Figure 3.3B). Consistent with
these overexpression studies, PDGFR  expression is downregulated in differentiating
Mesp1-deficient ESCs (data not shown).

Mesp1 binds to evolutionary conserved sites on the promoter region of PDGFR
The rapid and robust induction of PDGFR  by Mesp1 in differentiating ES cells
strongly suggested that it might be a direct Mesp1 target gene. Further studies were
performed to test this hypothesis. Two PDGFR transcripts (NM 011058 and NM
001083316), which have different promoters and 5’ UTRs but share the same proteincoding sequence, have been reported by NCBI. They were both induced in
differentiating A2lox.Mesp1 ESCs treated with Dox except transcript NM 011058 was
more abundant and showed a higher induction (data not shown). Therefore, NM 011058
might be a major PDGFR transcript induced by Mesp1 and was focused in the
following studies.
Eleven evolutionary conserved Mesp1 responsive elements (E-boxes) within the
15-kb PDGFR (NM 011058) promoter were identified (Figure 3.4A). To test whether
Mesp1 directly binds to these E-boxes, a dox-inducible, dual-expression A2lox.bioMesp1tetBirA ES cell line was generated. In this cell line, Mesp1 fused with a short
‘biotinylation peptide’ is induced by dox and serves as an in vivo substrate for
Escherichia coli biotin holoenzyme synthetase (BirA) which is simultaneously induced
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by dox. The binding abilities of these E-boxes to biotinylated Mesp1 in differentiating
A2lox.bio-Mesp1tetBirA ESCs treated with dox were tested by EMSA. Two E-boxes
(E4 and E8) were found to bind to biotinylated-Mesp1 and the bands were super-shifted
by anti-biotin antibody (Figure 3.4B). An evolutionary conserved E-box (E12) within the
promoter of PDGFR (NM 001083316) was found to bind to biotinylated-Mesp1 as well.
These E-boxes share the same consensus sequence CAAATG, which is the same as the
sequence published for Epha4 E3.66

PDGFR may be necessary for survival of Mesp1-induced mesodermal cells
Although PDGFR is robustly induced by Mesp1, it’s unclear what the functional
roles of PDGFR are and why Mesp1 induces it during ES cell differentiation. Although
PDGFR has only been used as an early mesoderm marker in ESC studies, it plays
important roles in a lot of biological processes, such as mesodermal cell migration and
survival during gastrulation, and EMT in various types of cancer.15,16,20,70,71 Therefore,
we hypothesize that PDGFR might be required for Mesp1 to induce EMT, mesoderm,
and/or to support mesodermal cell survival during ES cell differentiation.
To test the role of PDGFR during ES cell differentiation, AG1296, a kinase
inhibitor specific for PDGFR, was added to differentiating A2lox.Mesp1 ES cells with or
without dox treatment. In a dose-dependent manner, AG1296 blocked the induction of
early mesoderm markers (Flk1 and PDGFR) in both untreated A2lox.Mesp1 ES cells
and cells treated with a low dose of Dox (Figure 3.5A). However, I also noticed that less
live cells were detected by FACS analysis if the cells were treated with a higher dose of
AG1296 (Figure 3.5B), which suggested AG1296 might inhibit cell survival. The
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repression on early mesoderm induction might be a secondary effect of the death of
nascent mesodermal cells.

PDGFR is not sufficient for Mesp1 to induce EMT or mesoderm lineages
To test whether PDGFR is sufficient for any of Mesp1’s effects during ES cell
differentiation, gain-of-function studies were performed. Induction of PDGFR in ES
cells had no effects on Flk1 induction or E-cad downregulation in the presence or absence
of Dkk1 on both day 4 and day 5 of differentiation (Figure 3.6A-B). Addition of
PDGFR ligand PDGF-AA had little effects on Flk1 induction or E-cad downregulation
in differentiating A2lox.PDGFR ESCs either in the presence of absence of Dox (data
not shown). These data suggested that PDGFR is not sufficient to induce EMT and
mesoderm lineages as Mesp1.

31

A

B

Figure 3.1 Mesp2 has similar actions to Mesp1 on induction of mesoderm markers
and induction of EMT. A2lox.Mesp2 ES cells were differentiated in SCM for 4 days
with Dkk1 added on day 2, and with or without dox added on day 2. (A) Cells were
analyzed for PDGFR, Flk1, and E-cadherin expression on day 4 by flow cytometry. (B)
Snai1 and Gapdh expression in differentiated A2lox.Mesp2 cells was analyzed on day 4
by RT-PCR.
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Figure 3.2 Mesp1 rapidly induces expression of regulatory genes. (A) 293T cells
were transfected with firefly luciferase reporter constructs containing a minimal CMV
promoter (CMVmini), or enhancers for Epha4, Nkx2.5, or Myocd cloned upstream of
CMVmini, along with expression vectors for Mesp1 and E47, either separately or
together. Firefly luciferase activity was normalized using co-transfected Renilla
luciferase construct (prL-CMV). (B, C) A2lox.Mesp1 ES cells were differentiated in the
presence of Dkk1 without or with addition of dox on day 2. Gene expression was
evaluated by microarray. Shown is the log2 of the fold induction of selected transcription
factors (B) and signaling pathway genes (C), comparing samples treated with Dkk1 and
dox for 12 hours to samples treated only with Dkk1 during differentiation.
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Figure 3.3 Mesp1 induces PDGFR rapidly and in a dose-dependent manner. (A) A2lox.Mesp1 ESCs were differentiated in the
absence or presence of Dkk1 from days 2-6, either with or without 250 ng/ml dox from day 2-4. PDGFR Gene expression was
analyzed using microarray 6, 12, 24, 48, and 96 hr after Mesp1 induction. Shown is the fold increase of PDGFR in cells treated with
Dkk1 and dox compared to time-matched controls treated with Dkk1 only. (B) A2lox.Mesp1 ESCs were differentiated as in (A)
except the dose of dox was titrated. Cells were analyzed by flow cytometry for PDGFR and Flk1 expression.
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Figure 3.4 Mesp1 directly binds to the PDGFR promoter in vitro. (A) A schematic
of the evolutionary conserved E-boxes identified within the promoters of the two
PDGFR transcripts. The arrow indicates transcription start site for the specific
transcript of PDGFR. Core evolutionary conserved regions (ECR) and E-boxes between
the mouse and human are indicated as the solid black boxes and the red lines,
respectively. They are identified using the ECR Browser tool on the website:
http://www.dcode.org/. (B) Mesp1 binds to E4 and E8 within the promoter of transcript
NM_011058 and E12 within the promoter of transcript NM_001083316. A2.bioMesp1tetBirA ESCs were differentiated in the presence of Dkk1, with or without Dox
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(250 ng/ml) treatment on day 2. After 36 hr, cells were harvest and nuclear extract was
prepared for EMSA. Radiolabeled E4, E8 and E12 probes are incubated with nuclear
extract from cells treated with both Dkk1 and dox or with Dkk1 only, either in the
absence or presence of anti-biotin antibody. Epha4 E3 serves as a positive control. The
red arrow indicates the super-shifted bands.
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Figure 3.5 AG1296 blocked the induction of Flk1 and PDGFR in a dosedependent manner in untreated A2lox.Mesp1 ESCs or cells treated with a low dose
of dox. (A-B) A2lox.Mesp1 ESCs were differentiated without dox treatment (NT) or
with 10ng/ml or 100ng/ml dox treatment from days 2-4, in the absence (--) or presence of
an increasing dose of AG1296. On day 4, cells were analyzed by flow cytometry for
Flk1, and PDGFR expression. (A) The induction of Flk1 and PDGFR was inhibited in
NT or in 10ng/ml of dox-treated A2lox.Mesp1 ESCs by AG1296 in a dose-dependent
manner. Numbers indicate the percentage of live-gated cells within each quadrant. (B)
Less live cells were present in NT or in 10ng/ml of dox treated A2lox.Mesp1 ESCs with
a higher dose of AG1296, based on the FSC and SSC gating of all cells.
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Figure 3.6 PDGFR is not sufficient to induce EMT or Flk1+ mesoderm.
A2lox.PDGFR ESCs were differentiated as EBs without dox treatment (- dox) or with
250ng/ml dox treatment (+ dox) from days 2-4, in the absence (NT) or presence (Dkk1)
of Dkk1. On day 5, cells were analyzed by flow cytometry for Flk1, PDGFR and Ecadherin expression.
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CHAPTER 4: MESP1 LABELS ALL HEMATOPOIETIC LINEAGES AND
INDIRECTLY INDUCES MEIS1 IN ESC-DERIVED ENDOTHELIUM
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Mesp1 labels all hematopoietic lineages
Previously, we reported that the transcription factor Mesp1 regulates the
epithelial-mesenchymal transition (EMT) and promotes the cell fates of cardiomyocytes,
smooth muscle, and vascular endothelium from differentiating embryonic stem (ES)
cells.10 Mesp1 also reduces the in vitro development of hematopoietic lineages from ES
cells, although we did not establish if this action occurred in vivo. Since hematopoietic
stem cells (HSC) were shown to derive from hemogenic endothelium, 26-28 and Mesp1
regulates development of endothelium, we wondered if Mesp1 might influence gene
expression related to hematopoietic development.
Previous fate mapping studies showed that Mesp1 is expressed in the precursors
of the cardiovascular system including endothelium, endocardium, myocardium, and
epicardium,12 but did not carefully examine tracing of hematopoietic cells. We therefore
carried out fate mapping using Cre recombinase expressed by the Mesp1 locus with a
modified ROSA-GFP reporter locus (Figure 4.1A-B). Unexpectedly, we found that
hematopoietic cells were efficiently labeled by Mesp1-Cre, with different efficiencies
between individual animals ranging from 10% to as high as 99% of cells. Within a given
individual, the same percentage of hematopoietic cells was labeled by ROSA-GFP across
all hematopoietic lineages (Table 4.1). In particular, HSCs were labeled at the same
frequency as multi-potent progenitors (MPP), the megakaryocyte progenitors (MkP),
granulocyte-macrophage progenitors (GMP), and mature lineages derived from these
progenitors. Although the basis for individual animal variation is still unclear, these
results suggested that Mesp1 might be expressed in some fraction of hematopoietic
progenitors, possibly hemogenic endothelium.
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Mesp1 is necessary for hematopoietic differentiation of ESCs
Indeed, examination of Mesp1-deficient ES cells showed reduced numbers of
developing Tie2+ endothelial cells and CD41+ hematopoietic progenitors (Figure 4.2A) as
well as reduced hematopoietic development as assessed by methylcellulose assays
(Figure 4.2B). Mesp1 lineage tracing previously identified that Mesp1 labels the
endothelium of the dorsal aorta in the embryo. Since Mesp1 is not expressed in adult and
mature hematopoietic lineages (Figure 4.1C), these results suggest a potential role of
Mesp1 in optimal development of hemogenic endothelium.

Mesp1 indirectly induces Meis1 and Meis2 in ESC-derived endothelium
To test this, we purified Flk1+ Tie2+ endothelium derived from ES cell
differentiation as described10 (Figure 4.2C) and used microarray expression analysis to
identify genes strongly induced by Mesp1 (Figure 4.2D). The transcription factor Snai1
was strongly induced by Mesp1, as we previous reported.10 Unexpectedly, Mesp1 also
induced expression of Tlx1, required for spleen development,72 and both Meis1 associated
with both hematopoietic and endothelial development, 43,44 and Meis2.47 However, Mesp1
did not globally induce genes associated with hematopoietic development, since it
inhibited expression of Fli1,73 Etv2,74 Runx1,75 Cdx2,76 and Myb77 (Figure 4.2D). We
confirmed that Meis1 and Meis2 are indeed regulated by Mesp1, since both are reduced in
expression in ES cells that are deficient for Mesp1 (Figure 4.2E). However, the
regulation of Meis1 and Meis2 may be indirect, since Mesp1 could be demonstrated to
activate the Epha4 enhancer, but not the Meis1 or Meis2 promoter/enhancer regions
(Figure 4.2F).
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Table 4.1 Hematopoietic lineages labeled by Mesp1-Cre
Bone Marrow Progenitors
Mice#1
Mice#2
Mice#3

HSC
20.5%
31.3%
10.8%

MPP
25.5%
44.1%
9.5%

MkP
26.9%
38.1%
10.4%

GMP
26.1%
43.5%
11.2%

Pre GM
25.5%
47.8%
11.3%

Pre MegE
28.3%
41.1%
11.6%

Pre CFU-E
23.7%
35.8%
9.7%

CFU-E
25.1%
41.3%
11.5%

Spleen
Lymphoid

Mice#1
Mice#2
Mice#3

B220+
14.4%
26.1%
9.7%

CD3+ Granulocyte
20.4%
25.4%
37.6%
36.4%
14.4%
10.3%

Monocyte
24.3%
38.0%
10.1%

Myeloid
Inflammatory
DC
19.6%
32.0%
9.3%

Meg
+

CD4
DC
17.2%
31.8%
9.5%

Peripheral Blood
+

Mice#4
Mice#5
Mice#6

B220
14.5%
20.5%
97.9%

Lymphocyte
CD4+ B220- CD419.3%
17.0%
21.4%
19.2%
97.0%
94.0%

Granulocyte
16.6%
20.2%
99.7%

DC indicates dendritic cell; and pDC, plasmacytoid dendritic cell.
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Erythroblast

+

CD8
DC
pDC
20.0% 25.0%
32.3% 36.4%
9.1% 10.5%

CD41+
14.8%
31.4%
10.4%

Pro
Baso
17.4% 9.1%
33.6% 20.7%
10.3% 9.7%

Poly
12.4%
14.0%
1.7%

Ortho
1.3%
1.0%
0.1%

Figure 4.1 In vivo lineage tracing of myeloerythroid progenitors by Mesp1-Cre in
mouse bone marrow. Murine bone marrow cells collected from adult Mesp1Cre/+
Rosa26-CAG-STOP-eGFP+/+ mice were analyzed by FACS for GFP expression in
various myeloerythroid progenitors. (A) Bone marrow cells were stained with antibodies
to Sca1, c-kit, B220, CD41, CD105, CD150, and CD16/32. Shown is the gating scheme
used to identify progenitor populations LSK, HSC, MPP, MkP, GMP, CFU-E, Pre CFUE, Pre GM, and Pre MegE.78 (B) Shown are two-parameter contours for GFP expression
and forward scatter (FSC) for each indicated progenitor population from an individual
Mesp1Cre/+ Rosa26-CAG-STOP-eGFP+/+ mouse. Numbers indicate the percentage of
cells within the indicated gates. (C) Listed hematopoietic subsets were sort-purified
from 129S6/SvEV wild-type mice, harvested for RNA, and analyzed for the expression
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of Mesp1 by quantitative RT-PCR (n=3). RNA isolated from D4 A2lox.Mesp1 EBs with
or without dox treatment, and from Flk1+ Tie2+ cells sorted from D5 A2lox.Mesp1 EBs
with or without dox treatment were used as positive controls.
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Figure 4.2 Mesp1 induces a subset of hematopoietic-associated transcription factors
in ES cell-derived hemogenic endothelium. (A) ES cells derived from control
heterozygous Mesp1cre/+ mice (Mesp1cre/+) or homozygous Mesp1-deficient Mesp1cre/cre
mice (Mesp1cre/cre) as described previously24 were differentiated as embryoid bodies (EBs)
for 6 days and analyzed by FACS. Shown are two-parameter histograms for expression
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of CD41 and Tie2. Numbers indicate the percent of cells in the indicated quadrant. (B)
ES cells described in (A) were cultured as EBs for 6 days before plating in
methylcellulose media with cytokines as described in Methods. Hematopoietic colonies
were quantitated after 6 days growth on methylcellulose based on morphologies. Data
represent the average of three experiments. Error bars represent SD. (C) ES cells
harboring a doxycyline (dox)-inducible Mesp1 gene (A2lox.Mesp1) were differentiated
as embryoid bodies (EBs) for 5 days in the absence (-) or presence (+) of dox from day 2
to day 4. Flk1+ Tie2+ cells comprising between 5 and 10% of the population (Presort)
were purified by cell sorting (Postsort). (D) Microarray analysis of transcription factors
associated with hematopoietic development. Expression of the indicated genes is shown
as a ratio of expression values by dox-treated endothelial cells relative to untreated cells.
(E) Cells described in (A) were cultured as EBs for 5 days and total RNA was isolated to
detect the expression levels of the indicated genes by quantitative RT-PCR using primers
described in Table 2.1. (F) 293T cells were transfected with firefly luciferase reporter
constructs containing a minimal CMV promoter (CMVmini), CMVmini with Epha4
enhancer (Epha4), or 1kb upstream promoter/enhancer regions for Meis1 (Meis1) and
Meis2 (Meis2). These were co-transfected along with expression vectors for Mesp1 and
E47, either separately or together as indicated. Luciferase activity was normalized using
co-transfected Renilla luciferase construct (prL-CMV). Shown is the normalized
luciferase for the indicated constructs. Bars represent the SD of triplicate determinations.
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CHAPTER 5: DUAL ACTIONS OF MEIS1 INHIBIT ERYTHROID
PROGENITOR DEVELOPMENT AND SUSTAIN GENERAL
HEMATOPOIETIC CELL PROLIFERATION
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Meis1 and Meis2 promote hematopoietic colony formation from ES cells in vitro
To determine the activity of these Mesp1-induced genes in differentiating
endothelium, we generated ES cells with inducible Meis1 or Meis2 expression and
examined their differentiation in vitro by colony formation assay (Figure 5.1). Induction
of Meis1 caused a 5- to 6-fold increase in the numbers and size of definitive and mixed
hematopoietic colonies (Figure 5.1A-B), but had little effect on primitive erythroid
colonies. Meis2 also markedly increased numbers of definitive hematopoietic colonies
(Figure 5.1A) and increased their size (Figure 5.1B). In collagen-based media containing
thrombopoietin (TPO), induction of either Meis1 or Meis2 caused more than 4-fold
increase in the numbers of pure megakaryocyte colonies, and also increased the mixed
megakaryocyte colonies (Figure 5.1C-D). To facilitate analysis of hematopoietic
progenitors, we differentiated ES cells in liquid culture as embryoid bodies (EBs), and in
co-culture with OP9 cells,62 with or without cytokines (Figure 5.2A). We determined that
doxycycline induced approximately a 4-fold increase in Meis1 expression over the
endogenous Meis1, and more than 30-fold increase in Meis2 (Figure 5.2B). When
examined in EBs, Meis1 caused only a slight increase in expression of CD41, a marker
for the earliest hematopoietic progenitor 79 on day 9 of differentiation, but this effect was
lost by day 12 (Figure 5.2C). When examined in ES cells co-cultured with OP9 cells
alone, Meis1 produced a larger induction of CD41 on day 9, which again was lost by day
12. However, in ES cells co-cultured with OP9 and cytokines, Meis1 caused a robust
induction of CD41 in more than 50% of cells on day 9, and this effect persisted to day 12.
Therefore, we used these last conditions to further study Meis1 and Meis2 in regulating
hematopoietic differentiation.
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Meis1 increases most hematopoietic progenitors but inhibits early erythroid
progenitors
Previous studies suggested that Meis1 augments the proliferative potential of
various progenitor cells.38,47 Initially we expected that Meis1 and Meis2 might increase
all hematopoietic progenitors. Induction of Meis1 or Meis2 by doxycycline on day 7 and
8 increased the differentiation of CD71 - CD41+ hematopoietic progenitors by 50% to 200%
(Figure 5.3A). However, both factors decreased the number of early CD71 + erythroid
progenitors, consistent with the observed decrease in numbers of primitive erythroid
colonies in methylcellulose assays caused by Meis1 and Meis2 (Figure 5.1A).
Meis1 and Meis2 caused a substantial increase of the numbers and maintenance of
CD41+ hematopoietic progenitors on day 12 of differentiation (Figure 5.3B). Meis1 and
Meis2 induced the formation of two populations of CD41+ cells. One population
expressed intermediate levels of CD41 (CD41int), and the second expressed high levels
(CD41hi). The CD41int cells induced by Meis1 and Meis2 were negative for expression of
CD42d, a component of the von Willebrand factor receptor expressed by platelets.
Notably, CD41hi cells co-expressed CD42d, suggesting they are megakaryocytic
precursors. CD41int cells expressed a low frequency of c-kit or AA4.1/CD93, an early
hematopoietic progenitor marker, but expressed a higher frequency of CD45, a definitive
hematopoietic marker (Figure 5.3C). Notably, CD41hi cells induced by Meis1 were
largely negative for CD45, consistent with the lack of CD45 expression on
megakaryocytic precursors. Meis1 induced the development of macrophages compared
to control cultures (Figure 5.3C lower panels). These results identify two distinguishable
effects of Meis1 in differentiating ES cells. First, Meis1 increases the numbers of
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hematopoietic progenitors and maintains their persistence in culture. Second, and
unexpectedly, Meis1 skews hematopoietic differentiation by suppressing erythroid while
enhancing megakaryocytic progenitor differentiation.

Meis1 maintains proliferation of hematopoietic progenitors
The above actions of Meis1 could result either from increased proliferation or
decreased cell death of hematopoietic progenitors. To distinguish these possibilities, we
determined effect of Meis1 and Meis2 on the total number of CD41+ hematopoietic
progenitors (Figure 5.4A). Both Meis1 and Meis2 markedly increased the total
accumulation of CD41+ cells in culture, ranging from a 4-fold increase to more than a 10fold increase in total cells (Figure 5.4A). This indicates that the increase in percentages
of CD41+ populations seen earlier (Figure 5.3) represents an increase in total CD41+ cells.
We next measured proliferation directly using BrdU incorporation in vitro (Figure 5.4B).
Meis1 and Meis2 induced only slight increases in the rate of proliferation of CD41 + cells
on day 8, two days after transfer into OP9 cultures (Figure 5.4B upper panels). However,
Meis1 and Meis2 caused the maintenance of cell proliferation on day 11 (Figure 5.4B).
CD41+ cells in which Meis1 or Meis2 was not induced showed a marked decrease in
proliferation at this time, with only 20% of cells incorporating BrdU with a 3-hour pulse.
However, induction of Meis1 or Meis2 caused a rapid rate of proliferation to be
maintained even on day 11 (Figure 5.4B lower panels). This result is consistent with
Meis1 and Meis2 being able to maintain progenitor cells in a proliferative state, as has
been described previously.38,47
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Increased cell numbers could conceivably arise from decreased apoptosis of
CD41+ cells induced by Meis1. To test this, we stained differentiating ES cells in OP9
cultures with Annexin V and 7-AAD (Figure 5.4C). First, CD41+ cells undergoing
apoptosis (stained with Annexin V but not 7-AAD) were rare in ES/OP9 co-cultures,
being less than 5% either with or without induction of Meis1 or Meis2. Secondly, the
induction of Meis1 or Meis2 had no effect on the percentage of Annexin V+ cells,
indicating little effect of these factors on apoptosis of proliferating CD41 + progenitors.

Isoform-specific repression of in vivo erythroid progenitor development
Since Meis1 and Meis2 have multiple isoforms,44 we wished to test their actions
in regulating erythroid and megakaryocyte development. Meis1 has two naturally
occurring isoforms, Meis1a and Meis1b (Figure 5.5A), formed by an alternative splicing
of different terminal exons generating proteins with divergent C-terminal sequences.
Meis2 has at least six reported isoforms generated through alternative splicing (Figure
5.5A). We first tested whether the alternative isoforms of Meis1 and Meis2 had similar
effects on increasing CD41int hematopoietic progenitors (Figure 5.5B). Notably, Meis1a,
Meis2(2a), and Meis2(4a) each substantially increased the number of CD41int
hematopoietic progenitors on day 9 and day 12 relative to controls, indicating that these
isoforms act similarly to Meis1b and Meis2(2b) tested earlier (Figure 5.3B). Interestingly,
Meis1 and Meis2 appear to have different expression patterns in vivo. Meis1 is expressed
in hematopoietic progenitors, while Meis2 is expressed in the nervous system.80 We find
evidence for differential capacities of Meis1 and Meis2 isoforms to suppress erythroid
differentiation and promote megakaryocytic progenitors in vivo (Figure 5.6). First we
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used CD71 and CD41 expression to examine early erythroid progenitors from control
BM or from BM transduced with retroviruses expressing Meis1a, Meis1b, or Meis2(2b)
(Figure 5.6A). As a control, BM cells transduced with an empty retrovirus showed no
difference in the extent of erythroid progenitor development compared to non-transduced
BM within the same animal (Figure 5.6A left panel). As before, we found that
expression of Meis1b substantially reduced the population of CD71+ erythroid precursors,
and increased the population of CD41+ CD71- megakaryocyte progenitors. Notably,
Meis1a caused a greater reduction in development of erythroid progenitors, and a
stronger enhancement of CD41+ megakaryocyte progenitors compared to Meis1b. In
contrast, Meis2(2b) appeared weaker than Meis1b in these actions.
We repeated this analysis using CD105 and CD150 expression to distinguish
earlier stages of erythroid and megakaryocyte differentiation. CD150 + CD105population represents both the megakaryocyte-erythroid progenitor (MEP) and the
committed megakaryocyte progenitor (MkP). As the MEP differentiates towards the
erythrocyte lineage, CD105 expression is induced, followed by loss of CD150 expression.
In this system, again bone marrow cells transduced with an empty retrovirus showed very
little effect on the inhibition of erythrocyte differentiation. In contrast, Meis1b
substantially reduced the size of the CD105+ CD150- population of erythroid progenitors.
Again, the Meis1a isoform was even more robust in extinguishing erythroid progenitor
differentiation, and the Meis2(2b) isoform was much weaker than Meis1b or Meis1a.
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Figure 5.1 Meis1 and Meis2 increase the numbers of ES cell-derived definitive
hematopoietic colonies in semisolid media. (A) ES cells with dox-inducible Meis1
(A2lox.Meis1) or Meis2 (A2lox.Meis2) were differentiated as embryoid bodies (EBs) for
6 days before plating in methylcellulose media with cytokines as described in “Methods”.
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Hematopoietic colonies were quantitated after 6 days growth on methylcellulose based on
morphologies. Data represent the average of three experiments. Error bars represent SD.
(B) Bright field microscopy of definitive hematopoietic colonies derived from
A2lox.Meis1 or A2lox.Meis2 ES cells with (+) or without (-) treatment with doxycycline
(dox). Original magnification ×40. (C) A2lox.Meis1 or A2lox.Meis2 EBs were
dissociated on day 6 after differentiation and plated in MegaCult-C media. After another
6 days, megakaryocyte colony formation was visualized by acetylthiocholine iodide and
Harris hematoxylin counterstain, and CFU-Mk and mixed Mk colonies were quantitated.
Data represent the average of four experiments. Error bars represent SD. (D) Bright
field microscopy of CFU-Mk and mixed Mk colonies derived from A2lox.Meis1 ES cells
in the presence of dox. Original magnification ×100. CFU-Mk appeared brown, since
murine megakaryocytes express acetylcholinesterase, producing brown precipitate.
Mixed Mk colonies were distinguished by the presence of non-megakaryocytic cells
within brown-staining cell clusters.
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Figure 5.2 Meis1 maintains CD41+ hematopoietic progenitors from ES cells co-cultured with OP9 and hematopoietic
cytokines. (A) A2lox.Meis1 ES cells were differentiated as embryoid bodies (EBs) for 6 days. On day 6, EBs were left intact, or
dissociated and co-cultured with an OP9-GFP cell monolayer in the absence (OP9) or presence (OP9 + cytokines) of the cytokines
stem cell factor (SCF), thrombopoietin (TPO), vascular endothelial growth factor (VEGF), Flt3 ligand (Flt3L), interleukin-3 (IL-3)
and IL-6 (IL-6) as described in “Methods”. Doxycycline (dox) was added as indicated on day 6 and replenished every other day until
day 12. (B) A2lox.Meis1 and A2lox.Meis2 ES cells were differentiated as embryoid bodies (EBs) for 6 days and plated on OP9 cells
with cytokines described above in (A). Levels of Meis1 and Meis2 were determined by quantitative RT-PCR on day 7 or day 8 as
indicated in the presence or absence of doxycycline (dox) administered on day 6. (C) On day 9 and 12, cells from each different iation
condition were analyzed by FACS for expression of CD41 and CD42d. Numbers indicate the percentage of cells in the indicated
gates.
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Figure 5.3 Meis1 and Meis2 inhibit erythroid progenitor differentiation but increase CD41 + hematopoietic progenitors
differentiation from ES cells cultured on OP9 with hematopoietic cytokines. (A) A2lox.Meis1 or A2lox.Meis2 ES cells were
differentiated as EBs for 6 days before plating on OP9-GFP cell monolayers and cytokines, and treated with (+) or without (-)
doxycycline (dox) every 2 days until day 12. On day 7 and 8, cells were analyzed by FACS for CD71 and CD41 expression. Data
shown are for cells gated for negative expression of GFP to exclude OP9 cells from the analysis. Numbers indicate the percentage of
cells within each quadrant. (B) Cells were treated as in panel A and analyzed on day 9 and 12 for expression of CD42d and CD41. (C)
Cells were treated as in panel A and analyzed on day 12 for expression of c-kit, AA4.1, CD45, Mac1, and Gr1.
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Figure 5.4 Meis1 and Meis2 maintain the proliferation of CD41+ hematopoietic
progenitors from ES cells cultured on OP9 with hematopoietic cytokines. (A)
A2lox.Meis1 (left panel) or A2lox.Meis2 (right panel) ES cells were differentiated as in
Figure 5.3A and analyzed for total cell numbers and CD41 expression on the indicated
days. Absolute CD41+ cell numbers were determined from the product of total cell
counts and the percent of CD41+ expressing cells determined by FACS. (B) Cells
differentiated as in panel A were pulsed with BrdU for 3 hours on day 8 or 11 and
analyzed by FACS for CD41 expression and BrdU incorporation. Numbers indicate the
percentage of BrdU+ CD41+ cells. (C) Cells differentiated as in panel A were analyzed
by FACS for staining with Annexin V and 7-AAD to label apoptotic cells and with antiCD41 antibody to label hematopoietic progenitors. Numbers indicate the percentage of
CD41+ cells within each quadrant.

63

64

Figure 5.5 Isoforms of Meis1 and Meis2 maintain CD41+ hematopoietic progenitors differentiated from ES cells. (A) Shown is
the domain structure of Meis1 and Meis2 isoforms. Meis1a and Meis1b differ in the carboxyl-terminal (C-terminal) region due to
alternative splicing. Similarly, the C-terminal regions of Meis2(2a) and Meis2(4a) differ from Meis2(2b). (B) ES cells with doxinducible Meis1a (A2lox.Meis1a), Meis2(2a) (A2lox.Meis2(2a)), or Meis2(4a) (A2lox.Meis2(4a)) were differentiated and analyzed as
in Figure 5.3A.
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Figure 5.6 Meis1a and Meis1b inhibit the in vivo erythroid potential of the
megakaryocyte-erythroid progenitor (MEP). Stem/progenitor-cell-enriched bone
marrow cells from donor mice were transduced with a control vector (IRES-hCD4) or a
retroviral construct expressing Meis1a (Meis1a-IRES-hCD4), Meis1b (Meis1b-IREShCD4) or Meis2(2b) (Meis2(2b)-IRES-hCD4) as indicated. The transduced bone marrow
progenitor cells were transplanted into sub-lethally irradiated recipients and bone marrow
was analyzed 4 to 6 weeks later. (A) Bone marrow was analyzed for expression of hCD4,
B220, c-kit, CD71 and CD41. Shown are two-color contours of CD71 and CD41
expression for cells gated as B220 - c-kit+. Numbers indicate the percentage of cells in the
indicated gates. (B) The percentage of megakaryocytic progenitors (CD41+) or erythroid
progenitors (CD71+) as in panel A was determined for both transduced (hCD4+) cells and
non-transduced (hCD4-) cells within the same recipient. Shown is the ratio for each
vector for megakaryocytic progenitors (CD41+) or erythroid progenitors (CD71+) as
indicated. Each dot represents data from an individual recipient (n = 6). * P < 0.05, ** P
< 0.01, and *** P < 0.001. (C) Bone marrow from recipients described in panel A was
analyzed for expression of hCD4, B220, c-kit, Sca1, CD105 and CD150. Shown are twocolor contours of CD105 and CD150 expression for cells gated as B220 - c-kit+ Sca1-. (D)
The percentage of Pre MegE and MkP (CD105- CD150+), CFU-E (CD105+ CD150-), or
GMP and Pre GM (CD105- CD150-) progenitors was determined for both the transduced
(hCD4+) and non-transduced (hCD4-) bone marrow cells within the same recipient.
Shown is the ratio of hCD4+ to hCD4- progenitors for each construct and cell population.
Each dot represents data from one recipient mouse (n = 6). * P < 0.05, ** P < 0.01, and
*** P < 0.001.
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CHAPTER 6: IDENTIFICATION OF TRANSCRIPTIONAL TARGETS AND
BINDING PARTNERS OF MEIS1
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Identification of gene targets of Meis1
Having identified two distinct effects of Meis1, we wished to determine their
mechanisms. Meis1 might promote megakaryocyte-specific transcription factors or
suppress genes associated with erythrocyte development. In regulating hematopoietic
progenitor proliferation, Meis1 might directly induce genes associated with cell cycle, as
reported for the induction of cyclin D,47,54,81 or be involved in expressing growth factor
receptors that could support progenitor proliferation. To distinguish these possibilities,
we used microarray analysis to compare the various populations of cells developing in
ES/OP9 co-cultures in the presence and absence of Meis1 and Meis2 induction (Figure
6.1). To identify proximal gene targets of Meis1, we first needed to identify the critical
period of time in vitro during which Meis1 exerts its effects on proliferation and
differentiation. Thus, we carried out a temporal analysis of Meis1's actions on
hematopoietic cell development (Figure 6.1A). Optimal effects of Meis1 on inducing
CD41 were observed when Meis1 was induced on either day 4 or day 6 of ES cell
differentiation, but this effect was substantially reduced when induction of Meis1 was
delayed until day 8 of differentiation (Figure 6.1B). Induction after day 8 led to
essentially a loss of any activity of Meis1 induction on hematopoietic progenitor
development.
Therefore, to identify proximal targets of Meis1 in differentiating ES cells, we
induced Meis1 on day 6, and purified populations of CD41- and CD41+ cells 24 hours
after Meis1 induction (day 7), and CD41-, CD41int, and CD41hi populations 48 hours after
induction of Meis1 (day 8) (Figure 6.2A) and analyzed them by microarray (Figure 6.2BC). Notably, induction of Meis1 and Meis2 substantially decreased a number of
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erythrocyte-specific genes, including hemoglobin alpha (Hba-a1/2) and glycophorin A
(Gypa), both 24 hours and 48 hours after induction (Figure 6.2B). In addition, a number
of other genes associated with erythroid development were repressed by the induction of
Meis1 and Meis2 (Table 6.1). Expression of these erythroid genes was evident in CD41 +
populations, but absent from the CD41 - populations, as expected. Thus, Meis1 appears to
suppress erythrocyte gene expression within CD41 + hematopoietic progenitors, consistent
with inhibition of CD71+ erythroid progenitors (Figure 5.3A) and reduced primitive
erythroid colony formation (Figure 5.1A). This may be related to the requirement for
Meis1 in platelet development, given that Meis1-/- embryos die of vascular defects
secondary to the absence of platelets. 43-45
We also identified a few genes that were strongly induced by Meis1 and Meis2
(Figure 6.2C). Among these, placenta-specific 8 (Plac8), and serine peptidase inhibitor,
clade B, member 2 (Serpinb2) were strongly induced primarily in CD41 hi cells on day 8,
but induced by lesser amounts on day 7. Notably, the prostaglandin E receptor 3 (Ptger3)
was induced by Meis1 specifically in CD41+ cells both on day 7 and on day 8. We
verified that the known target of Meis1, the platelet factor 4 (Pf4) was also induced by
Meis1, and specific to CD41hi cells on day 8, consistent with its selective expression in
megakaryocytes and platelets (Figure 6.2C). The induction of Plac8 and Ptger3 by
Meis1 and Meis2 was confirmed by quantitative RT-PCR (Figure 6.2D).

Plac8 and Serpinb2
Next we turned to test the functional role of these three candidates in regulating
hematopoietic cell progenitor proliferation. Among these candidates, Ptger3 appeared to
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be conceivably related to hematopoietic progenitor proliferation, since its ligand
prostaglandin E2 can expand hematopoietic stem cells in the setting of
transplantation.82,83 However, Plac8 and Serpinb2 might conceivably regulate cell
proliferation or survival. Plac8 reportedly supports cell proliferation and survival by
modulating the Akt-Mdm2 pathway and P53 level, 84 while Serpinb2 may enhance tumor
cell survival.85 We tested Plac8 and Serpinb2 for their ability to influence accumulation
of CD41+ cells in ES cell differentiation cultures using a doxycycline inducible system
(Figure 6.3). However, induction of Plac8 or Serpinb2 alone or in combination showed
no effect on the accumulation of CD41+ cells or on the expression of CD42d either on
day 9 or day 12 in ES/OP9 co-cultures. Plac8-/- mice are able to generate normal
hematopoietic cell lineages, and only a slight influence on neutrophils function in an
infectious model system has been reported.86 Conceivably, Plac8 might provide a
proliferative advantage to hematopoietic progenitors that was obscured in the setting of
the knockout. To test this notion, we generated mixed bone marrow (BM) chimeras from
wild type and Plac8-/- donor mice (Figure 6.4). We compared the ability of Plac8-/- BM
progenitors to compete with wild-type progenitors across a wide range of stages of
hematopoietic development (Figure 6.4A). The ratio of chimerism observed for HSCs
was similar to the ratio in all subsequent stages of myeloerythroid differentiation,
indicating that loss of Plac8 does not influence progenitor proliferation relative to wildtype progenitors. Thus, Plac8 may be a target of Meis1 but does not appear to mediate its
effects on hematopoietic progenitor proliferation.
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Ptger3
Meis1 induced expression of Ptger3 in CD41+ cells on day 7, and in CD41 hi cells
on day 8 (Figure 6.2C). Ptger3 is expressed in the MkP at high levels relative to other
hematopoietic progenitors (Figure 6.5A). Meis1 expression is high in the MkP, but is
also expressed in other hematopoietic progenitors except for erythroid precursors (Figure
6.5B). To test whether signaling through this receptor could mediate Meis1's effect on
hematopoietic progenitor proliferation, we inhibited prostaglandin E receptor in the
presence or absence of Meis1 induction in differentiating ES cells (Figure 6.6). In the
absence of a prostaglandin E receptor antagonist SC-51322, both Meis1 and Meis2
induction caused a robust increase in the number of CD41int and CD41hi cells on day 12,
as expected (Figure 6.6A-C). However, in the induced conditions, increasing doses of
antagonist caused a statistically significant reduction in the CD41 int population generated
by overexpression of Meis1 and Meis2 (Figure 6.6B-C). The effect of this inhibition is
more evident in conditions in which Meis1 or Meis2 is induced by doxycycline relative to
the inhibition in the presence of endogenous levels of Meis1 or Meis2 (Figure 6.6A-C).
This may indicate that the actions of Meis1 and Meis2 in promoting hematopoietic
progenitor expansion may depend upon signaling through the Ptger3. However, the
inability of several shRNAs to significantly reduce endogenous Ptger3 expression in ES
cells prevents definitive determination of the requirement for this candidate in mediating
the effects of Meis1 (Figure 6.7).
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HoxA9 may not be the right partner for Meis1 in differentiating ESCs
Previous studies showed Meis1 interacts with Hoxa9 to accelerate leukemic
transformation,37 and Hoxa9 also modulates Meis1 to influence normal hematopoiesis.87
However, we found co-expression of Hoxa9 with Meis1 or Meis2 did not enhance
proliferation of CD41+ hematopoietic progenitors derived from ES/OP9 co-cultures
(Figure 6.8), suggesting either that Hoxa9 is not a binding partner of Meis1 during in
vitro hematopoietic differentiation of ES cells, or that Hoxa9 is not present in limiting
amounts in our system.
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Table 6.1 Erythroid genes down-regulated by Meis2
Gene
Symbol
Hba-a1/2
Hbb-y
Hba-x
Hbb-b1/2
Hbb-bh1
Gypa
Kel
Rhag
Tfrc
Cpox
Spna1
Slc25a37
Nfe2

Fold decrease (+dox/-dox)
D7_CD41+ D8_CD41int D8_CD41hi
-3.37
-6.33
-20.15
-2.22
-5.31
-12.12
-1.85
-3.19
-12.01
-1.66
-2.75
-4.77
-1.36
-2.36
-3.95
-2.45
-5.72
-7.05
-2.37
-1.40
-1.83
-1.80
-2.25
-3.02
-1.68
-1.53
-2.98
-2.50
-2.11
-3.00
-2.17
-2.22
-4.50
-1.63
-2.32
-4.26
-2.07
-1.85
-2.14
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Figure 6.1 Induction of Meis1 or Meis2 before day 8 of differentiation is required to maintain CD41 + hematopoietic
progenitors derived in ES/OP9 co-cultures. (A) A2lox.Meis1 or A2lox.Meis2 ES cells were differentiated as EBs for 6 days before
plating on OP9-GFP monolayers and cytokines as described in Figure 5.2A. Doxycycline (dox) was added on day 4, 6, 8, or 10 as
indicated and replenished every other day until day 12. (B) A2lox.Meis1 or A2lox.Meis2 ES cells from the conditions indicated in
panel A were analyzed on day 12 by FACS for CD41 and CD42d expression.
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Figure 6.2 Identification of Meis1 and Meis2 target genes. (A) A2lox.Meis1 or
A2lox.Meis2 ES cells were differentiated as in Figure 5.3A with or without treatment
with doxycycline, and were purified by cell sorting on day 7 or 8 into the indicated
populations based on levels of CD41 expression; CD41-, CD41+ (day 7) and CD41-,
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CD41int, and CD41hi (day 8). (B-C) Gene expression of A2lox.Meis2-derived
populations with (+) or without (-) treatment by doxycycline (dox) was determined by
microarray analysis. (B) Hemoglobin alpha (Hba-a1/2) and glycophorin A (Gypa)
expression is shown for the indicated populations treated with (+) or without (-) dox. (C)
Expression of placenta-specific 8 (Plac8), serine peptidase inhibitor, clade B, member 2
(Serpinb2), prostaglandin E receptor 3 (Ptger3) and platelet factor 4 (Pf4) is shown for
the indicated populations and conditions. (D) Expression of Plac8 and Ptger3 by CD41hi
day 8 cells treated with (+) or without (-) dox as described in panel A was determined by
quantitative RT-PCR.
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Figure 6.3 Plac8 and Serpinb2 are not sufficient to maintain CD41+ hematopoietic progenitors derived in ES/OP9 co-cultures.
ES cells with dox-inducible Plac8 (A2lox.Plac8), Serpinb2 (A2lox.Serpinb2), or both (A2lox.Plac8tetSerpinb2) were differentiated as
EBs for 6 days and co-cultured with OP9-GFP monolayers and cytokines as in Figure 5.2A. Doxycycline (dox) was added on day 6
and replenished every other day until day 12. On day 9 and 12, cells were analyzed by FACS for CD41 and CD42d expression.
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Figure 6.4 Plac8 is dispensable for normal in vivo hematopoietic progenitor proliferation. CD45.2+ bone marrow cells isolated
from Plac8-/- mice (KO) or wild-type (WT) littermate control mice were mixed with CD45.1 + competitor bone marrow cells from
B6.SJL-Ptprca/BoyAiTac at 1:1 ratio and transplanted into lethally irradiated B6.SJL-Ptprca/BoyAiTac recipients. Bone marrow from
recipients was analyzed by FACS after 4 weeks. (A) Cells were stained with antibodies against Sca1, c-kit, B220, CD41, CD105,
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CD150, CD45.1 and CD45.2. Shown are two-color histograms and gating scheme used to identify the populations indicated in
supplemental Figure 1. (B) Cells from recipients were stained as in panel A. Shown are two-color histograms for CD45.1 and
CD45.2 expression gated on the indicated populations as shown in panel A. Numbers are the percentage of cells in the indicated gates.
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Figure 6.5 Expression pattern of Ptger3 and Meis1 in adult hematopoietic subsets.
Expression values are shown for Ptger3 (A) and Meis1 (B) for each indicated cell
population derived from microarray analysis. 6 Data are assembled from two to four
replicate arrays.
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Figure 6.6 Meis1 and Meis2 induce CD41int hematopoietic progenitors through
Ptger3 signaling pathway. (A) A2lox.Meis1 or Meis2 ES cells were differentiated as
described in Figure 5.3A in the presence of the indicated concentration of SC-51322
added on day 6 and replenished daily. On day 9 cells were harvested and analyzed by
FACS for expression of CD42d and CD41. Cells are gated as GFP-negative to exclude
OP9 cells. Numbers indicate the percentage of CD41+ CD42d- cells developing in the
indicated conditions from three independent experiments. Bars indicate the SD. *
indicates P<0.05 and ** indicates P<0.01 from a paired students t-test. (B) A2lox.Meis1
ES cells were differentiated as in Figure 5.3A with the indicated concentration of SC51322 added on day 6 and replenished each day until day 12. On day 12, cells were
analyzed by FACS for expression of CD42d and CD41. Shown are data for GFPnegative cells to exclude analysis of OP9 cells. Numbers indicate the percentage of cells
in the indicated gates. (C) A2lox.Meis2 ES cells were differentiated and analyzed as in
panel A.
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Figure 6.7 Lack of extinction of Ptger3 mRNA after miR-based shRNA expression.
A2lox ES cell lines with constitutive expression of shRNA targeting Ptger3 were
differentiated and co-cultured with OP9 as described in Figure 5.3. On day 8, ESCs with
(Ptger3mir1-4) or without (Control) shRNA expression were collected and total RNA
was isolated. The extent of knockdown of the Ptger3 was assessed by quantitative RTPCR.
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Figure 6.8 HoxA9 is insufficient for maintaining CD41+ hematopoietic progenitors differentiated from ES cells either alone or
in combination with Meis1 or Meis2. A2lox.HoxA9 ESCs containing dox-inducible HoxA9, A2lox.Meis1tetHoxA9 ESCs
containing simultaneously dox-inducible Meis1 and HoxA9, and A2lox.HoxA9tetMeis2 ESCs containing simultaneously doxinducible Meis2 and HoxA9 were differentiated as in Figure 6.3. On day 9, cells were analyzed by FACS for CD41 and CD42d
expression. On day 12, cells were analyzed by for CD41 and c-kit expression.
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CHAPTER 7: DISCUSSION
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Correlation of in vivo and in vitro actions of Mesp1 and Mesp2 activity
Mesp1 was cloned by subtractive hybridization from the posterior primitive streak
of 7.5 day embryos.7 Mesp2, a closely related homolog located near the Mesp1 gene, was
cloned by homology to Mesp1.88 Mesp1 is required for normal heart development,
and Mesp1−/−embryos display early lethality.8 In Mesp1−/− mice in which β Gal is
targeted to the Mesp1 locus, β Gal-expressing cells accumulate in the primitive streak.8
However,Mesp1−/− embryos do generate cardiac mesoderm, although their heart tubes fail
to fuse, leading to cardia bifida and embryonic death.8 Mesp1−/− embryos also show
increased and prolonged expression of Mesp2 in the primitive streak, suggesting
that Mesp2 may compensate for migratory defects, but not for heart development seen
in Mesp1−/− embryos.12 In Mesp1−/−Mesp2−/− double-deficient embryos, there is an
accumulation of nonmigrating cells in the primitive streak and complete failure to form
cardiac mesoderm.12 Thus, Mesp1and Mesp2 may share potential transcriptional targets,
consistent with finding common induction of Snai1, but private functions may arise from
expression at distinct sites and times in the embryo, and verifying targets of Mesp1 in
vivo may require examination of Mesp1−/−Mesp2−/− embryos.

Transcriptional targets of Mesp1
Our previous study identified Snai1 and Myocd as early transcriptional targets of
Mesp1, representing plausible links to EMT and cardiovascular commitment, although
we have not determined whether these are direct Mesp1 targets.10 In this study, we
sought to identify the direct downstream targets of Mesp1 to reveal the mechanisms by
which Mesp1 acts. We found that Nkx2.5 and Myocd were not direct targets of Mesp1
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using reporter analysis. We also tested PDGFR, which was induced rapidly by Mesp1in
differentiating ESCs, and found Mesp1 directly bound to evolutionary conserved E-boxes
within the PDGFR enhancer/promoter. This result suggested that PDGFR could be a
direct target of Mesp1. However, we found that PDGFR was not sufficient for the
induction of EMT in ESCs or the induction of Flk1 + mesoderm, but that it may play a
role rather in the survival of Mesp1-induced mesodermal cells. Identifying the
mechanisms by which Mesp1 acts may be relevant to understanding cardiac development
and eventual applications to regenerative therapy.

Mesp1 and hematopoietic differentiation
Previous work documented primarily a cardiovascular pattern of lineage tracing,
with endothelium of the dorsal aorta also being labeled, where the definitive HSCs are
derived.89 Our previous study emphasized that the effect of Mesp1 in ES cultures was
predominantly to restrict fate to the smooth muscle and cardiovascular fates. However,
we clearly see labeling of mature hematopoietic lineages in a strongly mosaic pattern, an
indication that some mature cells derive from HSCs with a history of significant Mesp1
expression in their progenitors. This mosaic pattern of labeling in Mesp1-Cre mice
suggests the possibility of different sources of HSCs that give rise to the labeled mature
blood cells. Given recent progress in distinguishing HSCs of yolk sac from HSCs derived
from AGM, it will be interesting to see if Mesp1-traced blood tracks the actual origin of
Mesp1-labelled HCS that generate the labeled mature lineages in our study.
Using Mesp1-deficient ES cells, we showed Mesp1 is necessary for normal
hematopoietic differentiation of ESCs. In examining the downstream targets of Mesp1 in

89

ESC-derived endothelial cells, we identified myeloid ecotropic viral integration site 1
(Meis1). Using reporter assays, we further suggested that Mesp1 activated Meis1 in an
indirect manner.

The role of Meis1 in hematopoietic development
Meis1 was initially discovered as a common virus integration site for myeloid
leukimias,29 and much subsequent analysis has associated its actions with leukemic
transformation.37,41,90 However, the role of Meis1 in normal hematopoiesis is not well
studied. Our study identified two distinct roles of Meis1 during normal hematopoiesis
based on analysis of Mesp1-deficient ES cells and on analysis of overexpression of Meis1
and Meis2 (Figure 7.1). First, we observed a robust action of Meis1 to maintain the
proliferative state of early hematopoietic progenitors. Although previous study reported a
reduction of HSC population in the fetal liver of Meis1-/- mice,43,44 suggesting Meis1 may
play an important role in hematopoietic stem cell self-renewal, there is no direct evidence
that Meis1 acts on HSC proliferation. Our study demonstrated that Meis1 maintains a
proliferative state in CD41+ hematopoietic progenitors by directly measuring their BrdU
incorporation, which was associated with an increase of hematopoietic progenitors
accumulating in ES cell/OP9 co-cultures (Figure 5.4). Thus, our analysis extends our
understanding of how Meis1 promotes HSC self-renewal, unifying its action with those
described for Meis2 in regulating retinal progenitor cell proliferation during eye
development.47,81
Second, our study shows that Meis1 actively suppresses erythroid progenitor
differentiation while promoting megakaryocyte progenitor development. This previously

90

unrecognized action is very likely to underlie the defect in platelet development that has
been described as a basis for embryonic lethality in Meis1-/- mice.45 Our in vivo analysis
of bone marrow progenitors suggests that Meis1 regulated the early lineage decision
choice at the stage of the megakaryocyte-erythroid progenitor (MEP). In summary, our
study demonstrates dual actions of Meis1, distinguishing its later action on lineage
specification from its earlier role in HSC self-renewal.

Transcriptional targets of Meis1
In addition, our study identified novel gene targets of Meis1 to explain its actions
during normal hematopoiesis. We identified four potential candidates, Plac8, Ptger3,
Serpinb2, and Pf4, based on specific and robust induction by Meis1 in CD41+
hematopoietic progenitors. The platelet-specific gene Pf4/Cxcl4 is a chemokine-like
protein and a known target of Meis1.57 We tested whether the other three candidates
were sufficient or required for Meis1’s actions. Plac8 reportedly supports cell
proliferation and survival by decreasing p53 via the AKT-Mdm2 pathway.84 However,
we found it was neither sufficient to replace Meis1 for promoting hematopoietic cell
progenitor proliferation, nor necessary for maintaining in vivo hematopoietic stem cell
proliferation in a mixed bone marrow chimera setting. Likewise, we found Serpinb2 was
insufficient either alone or in combination with Plac8 for maintaining the persistence of
hematopoietic progenitors in ES/OP9 co-culture as Meis1. Several reports have
demonstrated that Meis1 can regulate progenitor cell proliferation through influencing the
expression of cell cycle components including cyclin D1 and cyclin D3.47,54,81 However,
our gene expression analysis identified no cell cycle components to be substantially
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altered by Meis1 in CD41+ hematopoietic progenitors. Instead, our study suggests a
novel mechanism by which Meis1 influences progenitor cell proliferation through
inducing a receptor for the prostaglandin signaling pathway. We found that Ptger3, one
of the four G-protein coupled receptors for prostaglandin E2, could potentially mediate
increased hematopoietic progenitor proliferation, since inhibition of prostaglandin
signaling blocked Meis1's effect on proliferation of hematopoietic progenitors.
Our study also identified that Meis1 robustly repressed a number of erythroidspecific genes including Hba-a1/2 and Gypa, consistent with an inhibitory role in
erythroid differentiation. At present, we do not distinguish between direct or indirect
actions of Meis1 on these target genes. Meis1 might directly recruit transcriptional corepressors to the target loci, or could induce repressors that can inhibit expression of
these erythroid-specific genes. In addition, other transcription factors such as Klf1 and
Fli1 have been reported to be critical regulators of erythroid and megakaryocyte
development.91,92 It will be interesting to examine the transcriptional hierarchy of Meis1
and these other factors in erythroid cell and megakaryocyte development. A dissection of
actions of Meis1 between early HSC proliferation and later erythroid and megakaryocyte
lineage specification should help in understanding the important functions of Meis1
during normal hematopoiesis.
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Figure 7.1 The role of Meis1 during hematopoietic development
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